Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
IGI partners with AbbVie and grants exclusive rights to globally develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China
Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
Opaganib has shown potential in enhancing ARPI treatment by blocking multiple enzymes involved in cancer cell survival.
Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access
The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls
TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Subscribe To Our Newsletter & Stay Updated
